Bayer's Pipeline Is Delivering Data — the Market Is Still Waiting for Dollars

Bayer shares drew two very different readings from the same batch of news this week. The stock added 3.9% to close at €45.65, with dpa-AFX pointing to China's approval of Asundexian alongside encouraging Darolutamid data as the trigger. That rally captures the optimism. It does not settle the question investors now face: how much of this medical progress actually converts into revenue.

The regulatory milestone is concrete enough. China cleared Asundexian under the brand name Sunharbo for reducing stroke risk following a non-cardioembolic ischemic stroke or a high-risk TIA. Bayer calls it the world's first approved Factor XIa inhibitor, and the decision rests on the Phase III OCEANIC-STROKE trial. In that study, dpa-AFX reported no higher rate of severe bleeding than with placebo.

One distinction matters here. An earlier Phase III trial of the drug in atrial fibrillation patients with stroke risk was halted early after a setback. The Chinese green light does not erase that failure — it covers a different patient population entirely.

Prostate Data Look Strong; the Survival Story Isn't Finished

For Nubeqa, the evidence comes from DASL-HiCaP, a Phase III study of 1,106 patients with localized prostate cancer at very high risk of recurrence. Added to hormone deprivation and radiation, the drug cut the risk of metastases or death by 58% versus placebo over a median follow-up of 3.8 years. No new safety issues surfaced.

Overall survival, though, shows only a positive trend so far — not robust results. Longer follow-up will be needed to pin down the durable benefit. And Darolutamid has not yet been approved for this particular treatment setting, which keeps the commercial upside tied to further regulatory steps.

Sizing the opportunity is where estimates start to diverge. Roughly 145,000 patients make up the DASL-HiCaP target population, though Bayer counts only the high-risk group as reachable. Nubeqa has already been used in about 123,000 patients worldwide. Those figures sketch the potential reach; they are not a promise of patients treated down the road.

Where the Analysts Part Ways

BofA's Sachin Jain sees high single-digit billion-euro peak sales potential for Nubeqa and reiterated a Buy rating on Bayer. Consensus for peak revenue sits near €5.5 billion — against the €4.7 billion peak that Xarelto reached. JPMorgan, meanwhile, sees the new data opening the door to an additional €1 billion in peak sales, according to media reports citing analyst Richard Vosser and a second research house. Jain projects high single-digit revenue growth for Bayer's pharmaceutical division from 2027 to 2032.

JPMorgan reaffirmed its Overweight rating and €61 price target, with Vosser taking a positive view of the DASL-HiCaP results. Jefferies was less moved. Analyst Michael Leuchten called the Darolutamid efficacy promising but read it more as confirmation of the known than a fundamental shift, keeping a Hold rating and a €46 target. The gap between those two numbers — €61 and €46 — is essentially the debate in miniature.

A Wider Pipeline, but Approvals Aren't Revenue

Bayer has more than one iron in the fire. On October 8, the FDA accepted a supplemental application for Finerenon in adults with chronic kidney disease without diabetes, backed by positive Phase III FIND-CKD results. Acceptance, however, is not approval.

Nor do the Darolutamid data substitute for a marketing authorization in the studied setting. Even the Asundexian approval in China establishes a regulatory win first — not the size of future sales. If expectations build faster than hard commercial results, the risk of disappointment grows.

The patent cliff has not gone away, either. Xarelto and Eylea face generic competition as their patents lapse, and new medicines must first offset that pressure before reliable growth emerges. Nubeqa itself has a US patent expiry dated to 2033, so lofty peak-sales estimates say little about how quickly Bayer can bank extra revenue or how long it stays protected.

Two Dates That Will Sharpen the Picture

The near-term catalyst is the US decision on Asundexian. An accelerated review is under way, with an outcome expected soon, according to dpa-AFX — though no confirmed decision date has been attached. China's approval is done; a corresponding US clearance is not.

Further out, ARASTEP results for Nubeqa are due in 2027, addressing an additional patient pool estimated at around 86,000. Before any of that, Bayer plans to publish third-quarter 2026 results on November 3, 2026. Those figures can sharpen the commercial baseline against which the drug hopes are judged — but they should not be mistaken for revenue already delivered by this week's approval.

What the market is really weighing, then, is not the count of positive headlines but the pace at which they turn into dependable business.